Imfinzi Is First Immunotherapy Approved for Advanced Non-small Cell Lung Cancer in US


Imfizi (durvalumab) has become the first approved immunotherapy in the United States for patients with advanced non-small cell lung cancer that has stabilized. Imfinzi is a human monoclonal antibody that binds to the programmed cell death 1 receptor, unleashing immune T-cells to attack cancer cells.